AMRS - Amyris, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.8400
-0.0700 (-2.41%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.9100
Open2.9100
Bid2.8200 x 1400
Ask2.9100 x 3200
Day's Range2.8300 - 2.9800
52 Week Range1.8700 - 6.0600
Volume1,130,682
Avg. Volume1,209,572
Market Cap307.416M
Beta (5Y Monthly)0.91
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    Clean Beauty Leader Biossance Lands in the UK

    Amyris, Inc. (Nasdaq: AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavours & Fragrances markets, is proud to announce the leader of clean beauty, Biossance™ is coming to the UK this month and is setting a new standard in the beauty industry's commitment to sustainable products. Biossance will land on Cult Beauty, which is one of the UK's fastest-growing online beauty businesses with significant market presence and a reputation for choosing the best performing, coolest cult products the world has to offer.

  • PR Newswire

    Amyris Provides Update - Achieves Record Fourth-Quarter 2019 Product Shipments; Clean Beauty Produces Breakout Performance

    Amyris, Inc. (Nasdaq: AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported record production for the fourth quarter of 2019. In addition, the company's Clean Beauty business continued its breakout performance.

  • PR Newswire

    Amyris Announces Successful Shipment of First Fermentation Derived Cannabinoid to LAVVAN and Provides Business Updates

    Amyris, Inc. (Nasdaq: AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported that it has successfully shipped the first cannabinoid to its partner, LAVVAN. Amyris is also well on its way to the shipment of a second cannabinoid in the first half of 2020.

  • PR Newswire

    WWD Beauty Inc Names Biossance Brand Digital Innovator Of The Year

    Biossance, a leading clean skincare brand from Amyris, Inc. (Nasdaq: AMRS), was recognized as Digital Innovator of the Year at the WWD Beauty Inc Awards for the launch of The Clean Academy, the brand's comprehensive, clean beauty education platform. Biossance President Catherine Gore accepted the award on behalf of the brand at a breakfast celebrating the winners on December 11 in New York.

  • PR Newswire

    SHAREHOLDER NOTICE: Scott+Scott Attorneys at Law LLP Continues Investigating Amyris, Inc.'s Directors and Officers for Breach of Fiduciary Duty - AMRS

    Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, continues investigating whether certain directors and officers of Amyris, Inc. ("Amyris" or the "Company") (NASDAQ: AMRS) breached their fiduciary duties to the Company and its shareholders. If you are an Amyris shareholder, you are encouraged to contact attorney Joe Pettigrew toll-free at (844) 818-6982 or at jpettigrew@scott-scott.com.

  • PR Newswire

    Biossance Leading the Clean Beauty Revolution with Biossance.com Cyber Monday Sales up over 3X from Last Year, Marking Highest One-Day Sales in Brand History

    Biossance, a pioneering clean skincare brand from Amyris, Inc. (Nasdaq:AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that its sales on Biossance.com for Cyber Monday, on December 2, were up over 3X from last year and resulted in the highest one-day sales in the brand's history. Product sales through Biossance.com have been comprising a greater portion of sales channel mix and these sales deliver much higher margins.

  • PR Newswire

    American Diabetes Association Announces Amyris CEO John Melo as Executive Committee Chair of 2020 Wine Country Tour de Cure

    EMERYVILLE, Calif., Nov. 19, 2019 /PRNewswire/ -- Today, the American Diabetes Association has announced that John Melo, President and CEO of Amyris, Inc. (AMRS) a science and technology company focused on Health & Clean Beauty, will chair the Executive Committee of the 2020 Wine Country Tour de Cure to be held on Sunday, May 3, 2020. Since its start in 1991, the Wine Country Tour de Cure has become a destination, marquis event for the Association annually raising millions of dollars for diabetes research, education and advocacy initiatives, including its #CountMeIn campaign.

  • PR Newswire

    Amyris Advances to Regulatory Stage with Another Significant Health & Nutrition Molecule

    EMERYVILLE, Calif., Nov. 18, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it is moving into the regulatory stage with a new, undisclosed health and nutrition molecule. Amyris has proven its capability to produce health and nutrition molecules at commercial scale with three others; artemisinin, vitamin E and, most recently, Reb M. Amyris developed a process for this ingredient that enables the highest purity at the lowest cost and has now successfully manufactured material via large scale fermentation. The company plans to submit formal regulatory filings for this ingredient (currently not being named due to partner's requirements) where required for rapid approval and market entry during the first half of 2020.

  • PR Newswire

    Amyris Closes on Exchange to Resolve CVI Heights Debt

    EMERYVILLE, Calif., Nov. 15, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that it has closed on its previously announced contemplated transactions providing for the purchase of its existing CVI Heights convertible note by two "accredited investors" (as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933) and subsequent exchange of such note for new unsecured convertible senior notes (the "Notes") in the amount of $66 million in a private exchange. The CVI Heights debt has been retired, thus curing the prior default of this debt. "We are pleased to have closed on these transactions and to have financed the resolution of our CVI Heights debt at a low coupon rate of 5%," said John Melo, Amyris President and CEO.

  • PR Newswire

    Amyris Executes Agreements to Resolve CVI Heights Debt

    EMERYVILLE, Calif., Nov. 11, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today announced that definitive agreements have been entered into providing for the purchase of its existing CVI Heights convertible note by two "accredited investors" (as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933) and subsequent exchange of such note for new unsecured convertible senior notes (the "Notes") in the amount of $66 million in a private exchange. As a result, the CVI Heights debt will be retired, thus curing the prior default of this debt, and Amyris will incur the new Notes as debt. The company can redeem the Notes at any time at a 15% premium to the greater of the principal amount or conversion value.

  • PR Newswire

    Amyris Continues to Deliver Strong Revenue Growth

    - Q3 2019 GAAP revenue of $35.0 million , up 144% over GAAP revenue of $14.3 million for Q3 2018 - Year to date GAAP revenue of $112.0 million , up 137% over $47.2 million for the prior year period - Product ...

  • Business Wire

    Haeggquist & Eck, LLP Investigates Amyris Officers and Directors Regarding Restatement of Financial Results

    Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether certain directors and officers of Amyris, Inc. (“Amyris” or the “Company”) (AMRS) breached their fiduciary duties to the Company and its shareholders. If you are an Amyris shareholder, you are encouraged to contact Amber Eck at Haeggquist & Eck for additional information. Amyris is an industrial biotech company that develops and produces chemical ingredients, including flavors and fragrance, cosmetics ingredients, pharmaceuticals, and nutraceuticals.

  • PR Newswire

    Amyris to Announce Third Quarter Financial Results on Thursday, November 7, 2019

    EMERYVILLE, Calif. , Oct. 23, 2019 /PRNewswire/ -- Amyris, Inc. (Nasdaq:AMRS) will report financial results for the third quarter ended September 30, 2019 after market close on Thursday, November 7, 2019 ...

  • WeissLaw LLP: Amyris, Inc. is the Subject of a Legal Investigation
    PR Newswire

    WeissLaw LLP: Amyris, Inc. is the Subject of a Legal Investigation

    NEW YORK, Oct. 18, 2019 /PRNewswire/ -- WeissLaw LLP, a national class action and shareholders' rights law firm with offices in New York, Los Angeles and Atlanta, announces the investigation of Amyris, Inc. (AMRS) ("AMRS," or the "Company"), its Board of Directors, and certain Company officers for, among other things, possible breaches of fiduciary duty and violations of federal securities laws.

  • PR Newswire

    Amyris Pipette Brand Successfully Launches on Amazon.com

    EMERYVILLE, Calif., Oct. 10, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable products for Health and Clean Beauty, today announced the successful launch of its Pipette brand on Amazon.com. As of October 3, Pipette was available at Pipettebaby.com, buybuyBABY.com, Amazon.com, and Dermstore.com with very strong early results and significant positive feedback from consumers. Pipette is expected to drive strong top-line sales performance for Amyris in the fourth quarter and beyond.

  • PR Newswire

    Amyris Files Form 10-Qs to Achieve Compliance - Notes Receipt of Nasdaq Deficiency Notification

    EMERYVILLE, Calif., Oct. 7, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS), a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, today reported that it has filed its required Forms 10-Q for the first quarter ended March 31, 2019 and the second quarter ended June 30, 2019. The company also noted that it has received a standard notice from Nasdaq stating that, as a result of not having timely filed these quarterly reports on Form 10-Q in accordance with the required September 30 deadline, it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. Upon the filing of the company's quarterly reports for the first and second quarters of 2019 on October 7, the company received a second notice from Nasdaq confirming that the company was again in compliance with the Rule and that, as a result, the company was no longer subject to Nasdaq's suspension and delisting procedures.

  • Biossance Introduces The Clean Academy
    PR Newswire

    Biossance Introduces The Clean Academy

    Leveraging Biossance's expertise in highly effective, sustainable beauty through biotechnology, The Clean Academy will educate about clean beauty through an interactive curriculum of fun and engaging video content, experiential events and a passionate community of industry experts. Guided by Biossance Brand Ambassador Jonathan Van Ness, as well as scientists, environmental activists, and more, The Clean Academy content will simplify complex concepts and ingredients so that everyone has the power to make smart choices, no matter where they are on their clean beauty journey.

  • PR Newswire

    Amyris Provides Highlights of First Half 2019 Financial Results

    EMERYVILLE, Calif., Oct. 1, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS) today provided highlights of its business and financial results for the first half of 2019 ended June 30, 2019, which it will review during a conference call after market close on Wednesday, October 2, 2019. The company also noted that it is has filed its 2018 Form 10-K and expects to file its Form 10-Qs for the first and second quarters of 2019 before the conference call on Wednesday. As a result of completing these filings, the company believes that it will have filed all of its delinquent SEC filings and be back in compliance with Nasdaq listing rules.

  • PR Newswire

    Amyris to Host First-Half 2019 Financial Results Teleconference on Wednesday, October 2, 2019

    EMERYVILLE, Calif., Sept. 27, 2019 /PRNewswire/ -- Amyris, Inc. (AMRS) today announced that it will review its financial results for the first half of 2019 ended June 30, 2019 after market close on Wednesday, October 2, 2019. The company is pleased to be able to hold its conference call to discuss financial results for the first half of 2019, as well as provide an update on the company's business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, October 2, 2019. The company will not be issuing a customary earnings release on its financial results prior to the call as the financial results for the first and second quarters of 2019 are anticipated to have been fully disclosed via the filing of required Form 10-Qs.

  • PR Newswire

    Amyris to Present at B. Riley FBR Annual Consumer & Media Conference on October 3, 2019

    Amyris will provide an update on its business and discuss its solid financial results for the first half of 2019 during the presentation, which is scheduled for Thursday, October 3, at 11:00 a.m. ET. A live webcast of the presentation including slides and a replay will be available on the investor relations section of the company's website at http://investors.amyris.com. Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products.

  • PR Newswire

    Clean Beauty Leader Biossance Enters the Australian and New Zealand Markets

    Known for pioneering the first renewably sourced, 100% plant-based squalane, the mega-moisture molecule that keeps skin healthy and hydrated, Biossance first launched in 2015, then followed with its No Compromise® campaign in 2016, underpinning the core of the brand, which bans in excess of 2,000 ingredients deemed to have safety and environmental concerns.

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amyris, Inc. - AMRS

    Pomerantz LLP is investigating claims on behalf of investors of  Amyris, Inc.  (“Amyris” or the “Company”) (NASDAQ: AMRS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On this news, Amyris’s stock price fell $1.76 per share, or 29.83%, to close at $4.14 per share on November 14, 2018.